Current FDA guidance on evaluating whether generic peptide drugs are truly equivalent to brand-name versions needs clarification on higher order structural assessment.
2021 FDA guidance issuedThe FDA's guidance for evaluating generic peptide drug sameness needs refinement as the first major peptide drug patents approach expiration
What the researchers found
Current FDA guidance for evaluating generic peptide drug sameness needs clarification on higher order structure assessment to ensure generic peptide drugs are safe and effective.
Why it matters
As patents expire on blockbuster peptide drugs, millions of patients could benefit from cheaper generic versions — but only if those generics are truly equivalent to the originals.
The numbers in context
The FDA issued final guidance in 2021. The market expansion is led by GLP-1 receptor agonists like semaglutide and liraglutide.
How the study worked
Regulatory science commentary and recommendation paper analyzing FDA guidance on generic peptide drug evaluation.
Who was studied
Regulatory analysis — no patient population
What this study cannot tell us
This is a policy recommendation paper, not a scientific study. The proposed clarifications have not yet been adopted by the FDA.
How to read the evidence
Rated preliminary: regulatory science commentary and recommendation paper, not a scientific study.
When this study was published
Published in 2024. Highly relevant as GLP-1 drug patents begin to expire and generic competition approaches.
The bigger picture
Millions of patients could benefit from cheaper generic versions of GLP-1 drugs. But peptide drugs are more complex than small molecules — their 3D structure affects how they work. Getting the rules right is essential for both access and safety.
Questions still open
- Will clarified rules accelerate or delay generic peptide drug approvals?
- Can analytical methods reliably detect all relevant structural differences?
Common questions
Will there be generic versions of semaglutide?
Why are generic peptides harder to make than generic pills?
Read the original research
Recommendation for Clarifying FDA Policy in Evaluating "Sameness" of Higher Order Structure for Generic Peptide Therapeutics.
The AAPS journal, 27(1), 8
Citation
Rogers-Crovak, Jessica A; Delaney, Edward J; Detlefsen, David J. (2024). Recommendation for Clarifying FDA Policy in Evaluating "Sameness" of Higher Order Structure for Generic Peptide Therapeutics.. The AAPS journal, 27(1), 8. https://doi.org/10.1208/s12248-024-00994-8